CAR T-Cell Therapy: Optimizing Collaboration, Referral, and Treatment

Download these slides from our live meeting series to review key strategies for integrating CAR T-cell therapy into community-based management of patients with hematologic malignancies.
Michael R. Bishop, MD
Jae H. Park, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.16 MB
Released: January 26, 2021


Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Bristol-Myers Squibb
Novartis Pharmaceuticals Corporation

Related Content

Clinical Care Options (CCO) expert podcast of top leukemia presentations from Hematology 2020: magrolimab in AML, asciminib in CML (ASCEMBL), ponatinib dosing in CML (OPTIC)

Jorge Cortes, MD Eunice S. Wang, MD Released: February 26, 2021

From Clinical Care Options (CCO), Drs. Jeff Sharman and John Burke review key data from studies of lymphomas and CLL treatment presented at ASH 2020

John M. Burke, MD Jeff P. Sharman, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 26, 2021 Expired: February 25, 2022

Domenica Lorusso, MD, PhD, on the molecular reclassification of endometrial cancers and key ongoing immunotherapy trials, from Clinical Care Options (CCO)

Domenica Lorusso, MD, PhD Released: February 25, 2021

Drs. Amy DeZern and Srdan Verstovsek discuss their top abstract choices from ASH 2020 in MDS and MPNs, from Clinical Care Options (CCO)

Amy E. DeZern, MD, MHS Srdan Verstovsek, MD, PhD Released: February 23, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.